轉移性癌症藥物市場－全球產業規模、佔有率、趨勢、機會和預測，按治療類型、癌症類型、最終用戶、地區和競爭細分，2020-2030 年

2024 年全球轉移性癌症藥物市場價值為 787.5 億美元，預計在預測期內將實現令人印象深刻的成長，到 2030 年的複合年成長率為 7.35%。全球轉移性癌症藥物市場是製藥業內至關重要且快速發展的領域，致力於開發已擴散到原發部位之外的癌症的先進療法。這些藥物旨在減緩腫瘤進展、控制症狀並提高患者的生活品質。

儘管取得了重大進展，但市場仍面臨關鍵挑戰，包括高昂的治療成本和某些癌症類型的進展有限。例如，胰臟癌仍然具有高度致命性，Folfirinox 等標準治療方法的療效有限。

然而，受癌症發病率上升、治療方法不斷創新以及行業戰略合作的推動，強勁的成長前景依然存在。為了確保市場持續擴張，解決治療的可負擔性和有效性問題（特別是對於難以治療的癌症）至關重要。

主要市場促進因素

轉移性癌症盛行率上升

主要市場挑戰

藥物開發成本與時間限制

主要市場趨勢

免疫療法占主導地位

研究人員正在探索免疫療法與其他治療方式（如標靶療法和化學療法）的結合，以提高反應率並克服抗藥性。

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第 4 章：顧客之聲

第5章：轉移性癌症藥物市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療類型（化療、免疫治療、荷爾蒙治療、標靶治療、其他）
  • 依癌症類型（乳癌、肺癌、攝護腺癌、黑色素瘤、大腸癌、其他）
  • 按最終使用者（醫院和診所、門診中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美轉移性癌症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第7章：歐洲轉移性癌症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太地區轉移性癌症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美洲轉移性癌症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第10章：中東和非洲轉移性癌症藥物市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 13 章：全球轉移性癌症藥物市場：SWOT 分析

第 14 章：競爭格局

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA.

第 15 章：策略建議

第16章調查會社について,免責事項

Global Metastatic Cancer Drugs Market was valued at USD 78.75 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.35% through 2030. The Global Metastatic Cancer Drugs Market is a vital and rapidly evolving sector within the pharmaceutical industry, dedicated to developing advanced therapies for cancers that have spread beyond their original site. These drugs are designed to slow tumor progression, manage symptoms, and enhance patients' quality of life.

Despite significant advancements, the market continues to face key challenges, including high treatment costs and limited progress in certain cancer types. For instance, pancreatic cancer remains highly lethal, with standard treatments such as Folfirinox offering only limited efficacy.

However, strong growth prospects remain, driven by rising cancer prevalence, continuous innovations in therapy, and strategic industry collaborations. To ensure sustained market expansion, addressing issues related to treatment affordability and effectiveness, particularly for hard-to-treat cancers, will be essential.

Key Market Drivers

The Rising Prevalence Of Metastatic Cancer

The rising prevalence of metastatic cancer is a significant market driver in the Global Metastatic Cancer Drugs Market. This phenomenon is multifaceted and can be attributed to several interconnected reasons, all of which have a substantial impact on the demand for metastatic cancer drugs.

One of the primary factors contributing to the increasing prevalence of metastatic cancer is the global demographic shift toward an aging population. As people age, their risk of developing cancer, including metastatic cancer, increases. This is because the incidence of cancer tends to rise with age, and as a result, there is a growing pool of potential patients requiring cancer treatment. Modern lifestyle choices have also played a pivotal role in the rising incidence of metastatic cancer. Factors such as poor diet, lack of physical activity, smoking, and excessive alcohol consumption are known risk factors for various types of cancer, including those that can metastasize. As these unhealthy habits become more prevalent in society, the occurrence of cancer cases, including metastatic ones, continues to rise. Environmental factors, including exposure to carcinogens and pollutants, have been linked to an increased risk of cancer. Industrialization, urbanization, and the expansion of certain industries have led to greater exposure to harmful substances, contributing to the incidence of metastatic cancer in some regions.

Key Market Challenges

Drug Development Costs and Time Constraints

Developing metastatic cancer drugs is a resource-intensive and time-consuming process. Clinical trials alone can take several years and cost billions of dollars. The need for extensive research, preclinical studies, regulatory approvals, and post-marketing surveillance significantly adds to the expenses and timelines. Additionally, the high attrition rate of experimental drugs during clinical trials further compounds the costs and extends development timelines.

Key Market Trends

Immunotherapy Dominance

Immunotherapy has emerged as a dominant trend in the treatment of metastatic cancer due to its remarkable efficacy and potential for long-lasting responses. Key factors contributing to this trend include:

Immunotherapies, such as immune checkpoint inhibitors (e.g., PD-1 and PD-L1 inhibitors) and CAR-T cell therapies, have demonstrated unprecedented success in treating certain metastatic cancers. Patients who had limited treatment options in the past are now experiencing durable responses and improved survival rates. Immunotherapy can be personalized based on a patient's immune profile and tumor characteristics. This tailoring of treatment enhances its effectiveness and minimizes adverse effects, making it an attractive option.

Researchers are exploring combinations of immunotherapies with other treatment modalities, such as targeted therapies and chemotherapy, to enhance response rates and overcome resistance.

Key Market Players

• Bristol-Myers Squibb Company
• Merck & Co., Inc.
• AstraZeneca Plc
• Novartis AG
• Eli Lilly & Co.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Amgen Inc.
• Sanofi SA

Report Scope:

In this report, the Global Metastatic Cancer Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Metastatic Cancer Drugs Market, By Therapy Type:

• Chemotherapy
• Immunotherapy
• Hormone Therapy
• Targeted Therapy
• Others

Metastatic Cancer Drugs Market, By Type of Cancer:

• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Melanoma
• Colorectal Cancer
• Others

Metastatic Cancer Drugs Market, By End User:

• Hospital & Clinics
• Ambulatory Centers
• Others

Metastatic Cancer Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Metastatic Cancer Drugs Market.

Available Customizations:

Global Metastatic Cancer Drugs market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Metastatic Cancer Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type (Chemotherapy, Immunotherapy, Hormone Therapy, Targeted Therapy, Others)
  • 5.2.2. By Type of Cancer (Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Colorectal Cancer, Others)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory Centers, Other)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Metastatic Cancer Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Type of Cancer
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Metastatic Cancer Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Type of Cancer
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Metastatic Cancer Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Type of Cancer
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Metastatic Cancer Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Type of Cancer
      • 6.3.3.2.3. By End User

7. Europe Metastatic Cancer Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Type of Cancer
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Metastatic Cancer Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Type of Cancer
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Metastatic Cancer Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Type of Cancer
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Metastatic Cancer Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Type of Cancer
      • 7.3.3.2.3. By End User
  • 7.3.4. France Metastatic Cancer Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Type of Cancer
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Metastatic Cancer Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Type of Cancer
      • 7.3.5.2.3. By End User

8. Asia-Pacific Metastatic Cancer Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Type of Cancer
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Metastatic Cancer Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Type of Cancer
      • 8.3.1.2.3. By End User
  • 8.3.2. India Metastatic Cancer Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Type of Cancer
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Metastatic Cancer Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Type of Cancer
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Metastatic Cancer Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Therapy Type
      • 8.3.4.2.2. By Type of Cancer
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Metastatic Cancer Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Therapy Type
      • 8.3.5.2.2. By Type of Cancer
      • 8.3.5.2.3. By End User

9. South America Metastatic Cancer Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Type of Cancer
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Metastatic Cancer Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Type of Cancer
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Metastatic Cancer Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Type of Cancer
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Metastatic Cancer Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Type of Cancer
      • 9.3.3.2.3. By End User

10. Middle East and Africa Metastatic Cancer Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapy Type
  • 10.2.2. By Type of Cancer
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Metastatic Cancer Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapy Type
      • 10.3.1.2.2. By Type of Cancer
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Metastatic Cancer Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapy Type
      • 10.3.2.2.2. By Type of Cancer
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Metastatic Cancer Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapy Type
      • 10.3.3.2.2. By Type of Cancer
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Metastatic Cancer Drugs Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Bristol-Myers Squibb Company
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Merck & Co., Inc.
• 14.3. AstraZeneca Plc
• 14.4. Novartis AG
• 14.5. Eli Lilly & Co.
• 14.6. Pfizer Inc.
• 14.7. F. Hoffmann-La Roche Ltd.
• 14.8. Johnson & Johnson
• 14.9. Amgen Inc.
• 14.10.Sanofi SA.

15. Strategic Recommendations

16. About Us & Disclaimer